Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario.
Basil G BerezaDoug CoyleDerek Y F SoZbigniew KadziolaGeorge WellsPaul GrootendorstEmmanuel A PapadimitropoulosPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
This translational study shows preference for a point of care PGx test.